Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Regen BioPharma, Inc. Announces Former Eli Lilly Executive And Current CVS Board Member Will Lead Newly Formed Business Advisory Board (BAB)

Summary

New (BAB)

NR2F6 is the Key to the Future

Focusing on Cancer & Auto Immune

Potential Buyout Target

Regen BioPharma, Inc.

CVS Health, Inc. Director Jean-Pierre Millon will serve as Chairman of the BAB, Roger Formisano and Robert Hopkins to serve as BAB board members for Regen BioPharma Inc.

SAN DIEGO, October 30, 2017 /PRNewswire/ --

Regen BioPharma, Inc. (RGBP) and (RGBPP) announced that former Eli Lilly executive Jean-Pierre Millon will serve as chairman of its newly formed business advisory board (BAB). The Company also announced that two esteemed life science and healthcare executives have agreed to serve as members of the BAB. The advisory board will assist Regen's management team in evaluating partnership and licensing opportunities related to the company's intellectual property including its NR2F6 program.

Read More:


The creation of the new (BAB) is another milestone and advancement in this growing Clinical Stage company.

These are exciting times for (OTCQB:RGBP) and the horizon in the near distance is full of promise.

Recent News/Current Events:

Regen BioPharma, Inc. Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6

PR Newswire October 23, 2017

Structures With and Without Small Molecules to be Determined

Regen BioPharma, Inc. Researchers Capitalize on Key Structure in Compounds that Activate Checkpoint NR2F6 for the Potential Treatment of Autoimmune Diseases

https://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/5050212-rgbp-nr2f6-nuclear-receptor-identified-demonstrates-important-immune-cell-inhibitor-and …

Partners – NIH (NCATS) - Pan Am Cancer Research and Treatment Center - Eli Lily & Company – Weill Cornell Medical College (Cornell University) - Chem Div

We believe Regen BioPharma is a Long Play, with a great upside with all the items in its Pipeline. Very possibly a Buy Out Target.

RGBP also has Short Term Gain Potential that has been proven time and again since we began following them. Increases-Bounces in Share Pricing ranging from 30%-400% and more at various intervals.

If you have any questions concerning (OTCQB:RGBP) or have a need for more information, please feel free to contact me. 

Robert E. Kreh - Principal

Small Cap Solutions, LLC

(443) 567-2609

robkreh@smallcapsolutions.com

robkreh@gmail.com 

(OTCQB:RGBP) Disclaimer:

You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at . Small Cap Solutions, LLC has received ($1000.00) cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclaimer: All Micro/Small Cap Company(ies) profile() are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at and/or Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.

Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker()/Broker Dealer() with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.